

New Members of the Editorial Board

Prof. Cestmir Altaner, PhD., DSc. graduated in 1957 with the highest distinction from the Slovak Technical University in Bratislava. He defended his Ph.D. thesis ("Tumour induction in rats by avian sarcoma virus B77") in 1969 at the Cancer Research Institute, Bratislava, and his D.Sc. thesis „The role of retroviruses in tumour induction" in 1983 at the Slovak Academy of Sciences. (D.Sc. is the highest scientific degree in Slovakia). In 1995 he became Associate Professor at the Comenius University, Bratislava.

In 1967 he worked at W. Goethe University, Frankfurt am Main, Germany, and in 1968-1969 in McArdle Laboratory for Cancer Research, University of Wisconsin, Madison, USA, supported by the Eleanor Roosevelt Cancer Fellowship of the American Cancer Society from the International Union Against Cancer, Geneva, Switzerland. Since 1983 he was repeatedly invited as „visiting scientist" to: Department of Molecular Biology, Brussels, Belgium, Molecular Biological Unit, Gembloux, Belgium, the University of Hiroshima, Japan, the Department of Virology, Biomedical Centre, University of Uppsala, Sweden. In 1994 he stayed for some time in the laboratory of Prof. H. M. Temin (Nobel Prize winner in medicine), McArdle Laboratory for Cancer Research, University of Wisconsin, Madison, supported by ICRET fellowship.

Prof. Altaner received several honours and awards for his scientific contributions: State Prize for achievements in the study of retroviruses (1983), a research grant from Fogarty International Centre, NIH, Bethesda (1992 – in collaboration with the laboratory of Nobel Prize winner Prof. H.M. Temin), J. Jessenius Award for Achievements in Medical Sciences (1993), Golden Medal of Slovak Academy of Sciences (1999) and FIRCA grant No. TW01217 of NIH, Bethesda.

Prof. Altaner is presently the Head of the Department of Molecular Virology, Cancer Research Institute, Slovak Academy of Sciences in Bratislava, Slovakia. Since 1995 he is also the Director of Cancer Research Institute. His main field of scientific interest is the study of molecular mechanisms of transformation of normal cell to cancer cell using retroviruses as an experimental tool. This includes also development of retroviral vectors for cancer gene therapy and detection of predisposition to cancer. Prof. Altaner is a reviewer of grant proposals to Czech and Slovak Grant Agencies and an expert in scientific evaluation of research projects for Ministry of Health and Ministry of Education of Czech Republic. Since 1994 he is a member of Scientific Council of the European School of Oncology (ESO), and since 2001 – a member of INTAS Council of Scientists.

He is an author of more than 100 original scientific papers published in international journals. He is also a Member of Editorial Board of the following journals: *Neoplasma* (Slovakia), *Folia Biologica* (Czech Republic), *Viral Immunology* (USA), *Journal of Experimental and Clinical Cancer Research* (Italy).

Prof. Dr. med. Michael Baumann graduated in 1988 from the Medical School University of Hamburg and received his Dr. med. title at the Institute of Biophysics and Radiobiology at this University. He was a Research Fellow, Department of Radiation Oncology, Massachusetts General Hospital, Harvard. He worked at the Department of Radiation Therapy, University Hospital Hamburg-Eppendorf and received his Habilitation in Radiation Oncology in 1994. Since 1998 he is Professor (Radiation Oncology) and Vice-Director of the Clinic of Radiation Therapy and Radiation Oncology, Medical Faculty Carl Gustav Carus in Dresden, Germany. Since 2000 he is also the Director of the Experimental Center of the Medical Faculty Carl Gustav Carus.

Prof. Baumann's main clinical interests are: lung cancer, head and neck cancer, sarcomas, clinical radiobiology, treatment planning and QA. He is principal investigator and co-investigator of several grants awarded by the Deutsche Forschungsgemeinschaft, the Deutsche Krebshilfe, and the Federal Ministry of Science. His research concentrates on radiobiology, tumour biology, and clinical trials (i.e. co-ordinator of the CHARTWEL-bronchus trial). He received several awards, including the G.E. Konjetzny-Award of the Hamburg Cancer Society (1995), the Hanns-Langendorff Award of the Vereinigung Deutscher Strahlenschutzärzte (1995) and the Gerhard Hess Award of the Deutsche Forschungsgemeinschaft (1997). He is also very active in ESTRO: as the Chairman of the Education and Training Committee, member of several scientific and ad hoc committees and a member of the teaching staff of the ESTRO course Basic Clinical Radiobiology.

Prof. Baumann published 96 papers (56 as first or senior author) and 1 book. He is the Editor of the *Experimentelle Strahlentherapie und klinische Strahlenbiologie* and a Member of the Editorial Board of *Radiotherapy and Oncology*, *International Journal of Radiation Biology*, *Strahlentherapie und Onkologie*.

Prof. Nirmal K. Gupta MBBS (Cal), FFR, FRCR (Eng), DMRT (London), was Deputy Director in Clinical Oncology, Christie Hospital NHS Trust, Manchester, UK until 1999; at present he is Honorary Consultant. He was also Lecturer in Radiotherapy and Oncology, University of Manchester (1975 -1999). He was Regional Post Graduate

Adviser and College Tutor, The Royal College of Radiologists, London and Member of the Council and of the Faculty Board, The Royal College of Radiologists. He was a Member, International Collaboration Group on „Fractionation Study”, American College of Radiologists, Member, UKCCR Sub-committee on Head and Neck Cancer, Chief Scientific Investigator on Computer Assisted Planning and Dosimetry in Head and Neck Cancer, International Atomic Energy Agency (IAEA), Vienna, Austria, Member, Expert Advisory Panel, IAEA, and WHO Consultant in Cancer Control Programme. He acted as WHO/IAEA Consultant in Malaysia, Cyprus, Egypt, Lithuania, Latvia and Estonia. He was invited as Guest Lecturer to over 40 international congresses.

Prof. Gupta is Honorary Member, Sociedad Peruana de Radiologica, Lima, Peru. He was Visiting Professor in Clinical Oncology at the University Nacional de la Plata, Argentina, and University Hospital, Zagreb, Croatia, and also a Consultant Radiation Oncologist, Regional Cancer Centre, St. John, NB, Canada. He published a chapter on Head and Neck Cancer in „The Radiotherapy of Malignant Diseases” (Springer Verlag 1985 and 1990) and numerous articles in leading journals. He is a reviewer for the *Journal of Clinical Oncology* and the *British Journal of Radiology*.

Prof. Anthony Howell received his BSc Hons (Anatomy/Cell Biology) London in 1965, MBBS (London) in 1968, MRCP (UK) in 1971, MSc (Biochemistry) London in 1974 and FRCP in 1986. His present appointment is: Professor of Medical Oncology, CRC Department of Medical Oncology, University of Manchester, Christie Hospital & Holt Radium Institute in Manchester, UK.

Prof. Howell is the Chairman of the UKCCR Breast Cancer Subcommittee, of the UKCCR HRT Working Party, of the Tamoxifen Prevention Trial and of the British Breast Group. He is also the Chairman of the European School of Oncology Breast Cancer Force, and a Member of the Nottingham International Breast Cancer Conference Organising Committee and of the Breast International Group. He is a referee of grant applications of Health Authority Research Committees, CRC and MRC, an external assessor, Institute of Cancer Research, and an external grant assessor for the Medical Research Council of Australia and Dutch Cancer Research Foundation. In addition to being a referee to such journals as the *Lancet*, *British Medical Journal*, *British Journal of Cancer*, *European Journal of Cancer* and many other, he is the Editor of *Breast News UKCCR* and *Breast Diseases* (with U. Veronesi et al), and a Member of the Editorial Board of *British Journal of Cancer*, *Endocrine Related Cancer* and *Women and Cancer Journal*.

Prof. Henning T. Mouridsen MD, PhD, graduated from the Copenhagen University in 1964 and received his PhD in 1972. He was Head, Department of Oncology, Finsen Institute (1976-90), Head, Department of Oncology, Rigshospitalet, Copenhagen (since 1990) and Research Professor (since 1995). He has been a Member, EORTC Bre-

ast Cancer Cooperative Group since 1972 and Chairman of this Group in 1980-83, Member, EORTC Sarcoma Group since 1974 and Chairman of this Group in 1990-93. He has been General Secretary of Danish Breast Cancer Cooperative Group and Member of several scientific DBCG subcommittees since 1977, Member, Scandinavian Soft Tissue Sarcoma Group since 1978 and Member of the Board of this Group in 1978-86. He has been Member, Early Breast Cancer Trialists Collaborative Group since 1985 and Chairman, 1985-89. He is also a Member of Danish Melanoma Group, Scandinavian Breast Group and Chairman, Clinical Trials Committee.

Prof. Mouridsen published over 220 papers in peer-reviewed journals and 22 chapters in books. He gave over 130 lectures at international congresses. He is also a Member of Editorial Boards of the *European Journal of Gynecological Oncology*, *Cancer Treatment Reviews*, *Acta Oncologica*, *European Journal of Cancer*, *Breast*, *Sarcoma*.

Prof. Lester J. Peters AM, MD, FRANZCR, FRCR, FACR is Director of Radiation Oncology at the Peter MacCallum Cancer Institute and the inaugural Professor of Radiation Oncology in the University of Melbourne School of Medicine. A graduate of the University of Queensland Medical School, he did his initial specialist post graduate training at the Queensland Radium Institute, obtaining the Fellowship of the Royal Australasian College of Radiologists in 1971. He then spent eight years in England and the USA pursuing radiobiological and clinical research at the Gray Laboratories of the Cancer Research Campaign and the University of Texas M D Anderson Cancer Center, respectively. In 1982 he was appointed Professor and Chairman of the Department of Radiotherapy at M D Anderson, a post that he held until taking up his current position in 1995. Over the past decade, his main research focus has been the integration of radiobiological knowledge into clinical practice with special reference to optimisation of radiation dose scheduling and development of protocols for combined chemo-radiotherapy regimens. Clinically, he is best known for his expertise in the treatment of head and neck cancers.

Prof. Peters was President and Chairman of the Board, American Society for Therapeutic Radiology and Oncology (ASTRO), Vice President, American Board of Radiology, Councillor to Radiation Research Society and International Association for Radiation Research, President, Gilbert H. Fletcher Society, Member, Board of Directors, International Society of Radiation Oncology, Chairman, International Congress on Radiation Oncology 2001. He is a member of many professional organisations and committees and is currently Chairman of the Medical & Scientific Committee of the Australian Cancer Society and President-Elect, Australian and New Zealand Head and Neck Society. He is also Roll of Honour Member, International Union Against Cancer, Janeway Lecturer and Gold Medalist, American Radium Society, Honorary Member of the Dutch Society for Radiation Oncology and Polish Oncological Society. He has a long-standing

interest in the training and certification of radiation oncologists and in the ongoing maintenance of professional standards. In 2001, he received the award of Member of the Order of Australia „for service to medical research education and clinical practice in the field of radiation oncology, resulting in improved treatments for people with cancer, particularly in the head and neck region”. Prof. Peters has over 220 papers published in peer-reviewed journals as well as 90 invited papers and book chapters. He is Associate Editor of *Cancer Research*, *Radiation Research* and *Clinical and Experimental Metastasis*, and Member of the Editorial Board of *International Journal of Radiation Oncology, Biology, Physics, Radiotherapy and Oncology*, *European Journal of Cancer*, *Journal of the National Cancer Institute*, *Cancer Bulletin*, *Head and Neck*, *Journal of the Japanese Society for Therapeutic Radiology and Oncology* and *Journal of Clinical Radiotherapy and Oncology*.

Prof. Zev Wajzman, M.D., FRCS(C), FACS, graduated in 1963 from the Medical School, Hebrew University, Hadassah, Jerusalem, Israel. His many further professional appointments included: Urologic Oncology Clinical Fellow, Department of Urology (1973-1975) and Cancer Research Clinician, Department of Experimental Surgery (1976-79), Roswell Park Memorial Institute, Buffalo, New York, Assistant Professor of Surgery/Urology, State University of New York at Buffalo (1977-80) and Associate Chief, Department of Urologic Oncology, Roswell Park Memorial Institute, Buffalo, USA. He was Clinical Consultant, National Prostatic Cancer Project, Principal Investigator, National Bladder Cancer Collaborative Group, and Member, SESUA Board of Directors and Research Committee

Prof. Wajzman is now Professor of Surgery, David A. Cofrin Professor and Chief, Urologic Oncology, Director, Urology Residency Program, Division of Urology, Department of Surgery, University of Florida College of Medicine in Gainesville, Florida, USA. He is a member of several professional societies and advisory committees and an acting President of Florida Urological Society. His list of honours and awards includes: Letter of Award, International Cancer Research Technology Transfer (ICRETT) Program, Honorary Membership of Peruvian Urological Association and Polish Urological Association, Honorary Degree – Jagiellonian University, Cracow, Research Appreciation Award: BCG/Intron – A National Phase II Bladder Cancer Trial. He was Guest Speaker, American Cancer Society Science Writers, and European Urological Association

Prof. Wajzman is an author of over 130 original papers, 20 book chapters and numerous invited lectures. He was Visiting Professor in several scientific institutions in the USA, Peru, Holland, Israel and Poland. He is a Member of the Editorial Board of *Journal of Surgical Oncology*, *Journal of PDQ-NCI* and *Cancer Research, Therapy and Control*.